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ABSTRACT
We formerly demonstrated that vaccination with Wilms’ tumor 1 (WT1)-loaded 
autologous monocyte-derived dendritic cells (mo-DCs) can be a well-tolerated 
effective treatment in acute myeloid leukemia (AML) patients. Here, we investigated 
whether we could introduce the receptor for hyaluronic acid-mediated motility 
(RHAMM/HMMR/CD168), another clinically relevant tumor-associated antigen, into 
these mo-DCs through mRNA electroporation and elicit RHAMM-specific immune 
responses. While RHAMM mRNA electroporation significantly increased RHAMM 
protein expression by mo-DCs, our data indicate that classical mo-DCs already express 
and present RHAMM at sufficient levels to activate RHAMM-specific T cells, regardless 
of electroporation. Moreover, we found that RHAMM-specific T cells are present at 
vaccination sites in AML patients. Our findings implicate that we and others who are 
using classical mo-DCs for cancer immunotherapy are already vaccinating against 
RHAMM.
INTRODUCTION
Despite major advances over the past decades, the 
prognosis of acute myeloid leukemia (AML) remains 
poor due to frequent relapse, which is related to minimal 
residual disease following initial treatment [1]. This holds 
particularly true for the large group of older patients with 
comorbidity deemed unfit to undergo intensive treatment 
and for whom median survival is less than one year. 
Immunotherapy, including dendritic cell (DC) vaccination, 
might offer an alternative. We demonstrated in a phase 
I/II clinical trial that autologous dendritic cells (DCs) 
loaded with the tumor-associated antigen (TAA) Wilms’ 
tumor 1 (WT1) by mRNA electroporation can induce 
clinical responses in AML patients with very limited side 
effects [2]. Because of the favorable toxicity profile and 
promising results in early phase clinical trials by ourselves 
and others, DC vaccination is widely under investigation 
in the treatment of various solid and hematological 
malignancies [2–4]. Simultaneously, research efforts are 
directed towards new strategies to improve the efficacy 
of DC vaccination, as objective and durable clinical 
responses are currently limited to a small minority of 
cancer patients [3–5].
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Much interest goes to boosting the 
immunostimulatory properties of existing clinical DC 
vaccination protocols in order to improve their efficacy. 
It has become increasingly evident that the clinical 
success of DC vaccination – and immunotherapy in 
general – is hampered by cancer cells escaping immune 
control by passively and actively evading and suppressing 
immunity [6, 7]. The ideal DC vaccine should therefore 
contain potent immunostimulatory DCs that can activate 
a broad repertoire of tumor cell-specific T cells through 
presentation of different TAAs.
Correspondingly, adding another TAA, next to WT1, 
to our clinically used DCs would allow for a multi-antigen 
vaccine that may help withstand cancer immune escape 
in a more efficient manner. The receptor for hyaluronic 
acid-mediated motility (RHAMM/HMMR/CD168) is 
considered an interesting target for cancer immunotherapy, 
because it is a TAA expressed by a broad variety of 
hematological malignancies and solid tumors which is 
linked to tumor progression and has prognostic relevance 
[8–16]. In addition, murine bone marrow-derived 
DCs transfected with RHAMM mRNA were shown to 
significantly improve survival in a mouse glioma model 
[17]. Even if RHAMM was not overexpressed in leukemic 
cells with a stem cell immunophenotype, [18] RHAMM-
specific T cells were able to control tumor growth in 
human xenograft solid tumor and disseminated AML 
mouse models [19]. Most importantly, clinical trials with 
RHAMM peptide vaccination have already demonstrated 
immunological and clinical responses in patients with 
various hematological malignancies, including AML, 
chronic lymphocytic leukemia, multiple myeloma and 
myelodysplastic syndrome [20–22].
In the present work, we examined whether RHAMM 
could be introduced into the human monocyte-derived (mo-)
DCs we use in our cancer vaccine clinical trials through 
mRNA electroporation, and whether these DCs then present 
RHAMM and activate RHAMM-specific T cells.
RESULTS
RHAMM mRNA electroporation increases 
RHAMM protein expression by mo-DCs
We first tested whether DCs express RHAMM 
following mRNA electroporation by examining RHAMM 
protein levels in non EP DCs, mock EP DCs and RHAMM 
EP DCs using intracellular staining. RHAMM EP 
DCs clearly expressed the RHAMM protein following 
electroporation, as mean fluorescence intensity (MFI) 
of samples stained for RHAMM far exceeded that of 
the respective isotype stained control samples (MFI 
17.7 and 3.5, respectively; p < 0.001; n = 3; Figure 1). 
These RHAMM protein levels in RHAMM EP DCs were 
significantly higher than those in non EP DCs and mock 
EP DCs (MFI 5.7 and 5.5, respectively; p < 0.001; n = 3; 
Figure 1). Interestingly, MFI of non EP DCs and mock 
EP DCs stained for RHAMM was higher than that of 
their respective isotype stained control samples (MFI 3.4 
and 3.4, respectively; p < 0.05; n = 3; Figure 1). These 
data show that RHAMM mRNA electroporation of DCs 
leads to increased RHAMM protein expression, but also 
suggest that RHAMM is already expressed by mo-DCs 
irrespective of electroporation.
RHAMM mRNA is expressed by mo-DCs
To verify whether RHAMM is expressed by mo-
DCs, we quantified RHAMM mRNA levels in monocytes, 
non EP DCs and mock EP DCs by quantitative real-time 
polymerase chain reaction (qPCR). Freshly isolated 
monocytes displayed low background RHAMM mRNA 
expression when normalized for two household genes 
(mean [2-ΔCt x 10-3] 0.2; n = 3; Figure 2). Conversely, 
non EP DCs and mock EP DCs expressed detectable 
levels of RHAMM mRNA (mean [2-ΔCt x 10-3] 2.2 and 2.9, 
respectively; n = 3; Figure 2). In addition to the evidence 
on protein level, these results confirm on the mRNA level 
that mo-DCs express RHAMM.
Mo-DCs present RHAMM and activate 
RHAMM-specific cytotoxic T cells regardless of 
RHAMM mRNA electroporation
After establishing that mo-DCs express RHAMM, 
we sought to determine whether they can also activate 
RHAMM-specific CD8+ cytotoxic T cells through 
presentation of RHAMM epitopes in a human leukocyte 
antigen (HLA)-dependent manner. Mock EP DCs and 
RHAMM EP DCs from HLA-A*0201- or A*0201+ donors 
were evaluated for their capacity to induce IFN-γ secretion 
or CD137, CD107a and granzyme B expression by the 
RHAMM R3-specific CD8+ cytotoxic T cell clone. T 
cells stimulated with mock EP DCs or RHAMM EP DCs 
from HLA-A*0201- donors did not secrete more IFN-γ 
than T cells cultured alone (medium control; Figure 3). In 
contrast, culture with mock EP DCs or RHAMM EP DCs 
from HLA-A*0201+ donors significantly increased IFN-γ 
secretion by T cells (Figure 3). Despite notable differences 
in RHAMM protein expression, stimulation with mock 
EP DCs or RHAMM EP DCs from HLA-A*0201+ donors 
resulted in similar levels of IFN-γ secretion (mean 6.4 and 
6.2 ng/105 T cells, respectively; n = 3; Figure 3). Likewise, 
culture with mock EP DCs or RHAMM EP DCs from 
HLA-A*0201+ donors induced virtually equal levels of 
CD137, CD107a and granzyme B expression by T cells 
(Figure 3). These data indicate that mo-DCs present 
RHAMM and activate cytotoxic CD8+ T cells specific 
for this TAA in an HLA-dependent manner, and that this 
activation is not enhanced by increasing RHAMM protein 
expression via mRNA electroporation.
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Clinical vaccine WT1-loaded mo-DCs from AML 
patients express and present RHAMM
We investigated RHAMM expression and 
presentation by thawed AML patients’ WT1 EP DCs 
used in our clinical vaccination trials. Similar to mo-
DCs from healthy donors, AML patient WT1 EP DCs 
showed RHAMM protein expression levels which 
were comparable to that of non EP DCs from the 
same respective patients and exceeded isotype control 
background staining (n = 4; Figure 4). Moreover, we 
found that WT1 EP DCs from HLA-A*0201+ AML 
patient donors strongly stimulated IFN-γ secretion by the 
RHAMM R3-specific CD8+ cytotoxic T cell clone whereas 
those from HLA-A*0201- AML patient donors did not 
(mean 7.3 and 0.8 ng/105 T cells, respectively; p < 0.01; n 
= 3 and 2, respectively; Figure 5). These results show that 
the WT1-loaded mo-DCs used as autologous vaccines in 
AML patients also express the TAA RHAMM at sufficient 
levels to potently activate RHAMM-specific cytotoxic 
CD8+ T cells in an HLA-dependent manner.
RHAMM-specific T cells are present in 
vaccination sites in AML patients
Finally, we examined in vivo T cell responses in 
HLA-A*0201+ AML patients vaccinated with WT1 EP 
DCs for the presence of RHAMM-specific T cells. The 
proportion of RHAMM R3- and R5-specific cells within 
the CD8+ T cell population infiltrating the injection sites 
of the vaccine (i.e. WT1 EP DCs) or keyhole limpet 
hemocyanin (KLH) alone, in the context of a delayed 
type hypersensitivity (DTH) skin test, was measured by 
flow cytometry following staining with R3 or R5 peptide-
loaded (p)HLA-A*0201 tetramers. The percentages of 
RHAMM R3- and R5-specific T cells within the CD8+ 
T cell population isolated from the vaccine injection site 
(mean 0.089 and 0.075%, respectively; n = 6; Figure 6) 
were higher than those in the population isolated from the 
KLH injection site (mean 0.006 and 0.004%, respectively; 
n = 3; Figure 6). These differences were statistically 
significant for the R5 epitope and demonstrate that 
RHAMM-specific T cells are found at the injection sites 
Figure 1: RHAMM protein expression in DCs. Four hours after electroporation, non EP DCs, mock EP DCs and RHAMM EP DCs 
were stained with LIVE/DEAD® Fixable Red Stain prior to two-step intracellular staining with RHAMM or isotype control mouse IgG1 
antibody and rat anti-mouse IgG1-PE. Samples were acquired on a FACScan flow cytometer. The histogram overlay shows PE staining 
levels of isotype stained RHAMM EP DCs (grey filled area) or RHAMM stained non EP DCs (dotted black line), mock EP DCs (dashed 
black line) and RHAMM EP DCs (full black line) from one representative donor. PE staining is further depicted as mean fluorescence 
intensity (+ SD) of viable (LIVE/DEAD-) DCs from 3 independent donors; *P < 0.05, ***P < 0.001, one-way ANOVA with Bonferroni 
posthoc test. MFI, mean fluorescence intensity.
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of AML patients vaccinated with mo-DCs that were not 
specifically loaded with RHAMM mRNA.
DISCUSSION
Clinical trials by our group and others have 
demonstrated that DC vaccination can induce objective 
clinical responses in cancer patients without significant 
toxicity, but at the same time highlighted that new 
strategies are needed to improve the efficacy of DC 
vaccination [2–5]. RHAMM is considered a promising 
and clinically relevant TAA, with studies showing that 
RHAMM peptide vaccination and RHAMM-specific 
immune responses can yield clinical effects [19–21]. We 
hypothesized that introducing RHAMM into our clinically 
used DC vaccine through mRNA electroporation might 
enhance efficacy by broadening the scope of anti-TAA 
immunity.
We first electroporated human mo-DCs with 
RHAMM mRNA and showed that this approach resulted 
in the expression of increased levels of RHAMM 
protein in mo-DCs. Interestingly, mo-DCs that were not 
electroporated or were electroporated without RHAMM 
mRNA also expressed RHAMM, albeit at lower levels. 
Natural RHAMM mRNA expression in these cells was 
further confirmed by qPCR. Other studies already 
reported that RHAMM expression is not restricted to 
malignant cells but is also found at varying levels in 
different normal cells and tissues, including testis and 
spermatocytes, placenta, thymus, the eye, parts of the 
gastro-intestinal mucosa, normal proliferating CD34+ cells 
and activated T cells [8, 15, 16, 18, 23]. Yet, this is the 
first report describing RHAMM expression by classical 
mo-DCs. This is most probably an effect resulting from 
cytokine stimulation and differentiation during in vitro 
culture, considering the virtual absence in monocytes 
and upregulation of RHAMM expression in other normal 
activated or dividing cells [18, 24–26].
We further showed that mock EP DCs induced 
similar levels of IFN-γ secretion and CD137, CD107a and 
granzyme B expression by RHAMM-specific T cells as 
compared to their RHAMM EP DC counterparts, despite 
the higher RHAMM protein levels found in the latter. 
This indicates that the basal levels of RHAMM expressed 
by mo-DCs are already sufficient to surpass the antigen 
threshold for T cell activation, which is in line with the 
observation that very few peptide/HLA complexes are 
required for the induction of complete T cell activation 
[27]. Presentation of TAAs that are expressed by in 
vitro generated DCs may at least in part explain why 
administration of TAA-“unloaded” DCs is able to inhibit 
tumor growth in mouse cancer models [28, 29]. On the 
Figure 2: Native RHAMM mRNA expression levels in monocytes and mo-DCs. Total cDNA from monocytes, non EP DCs 
and mock EP DCs served as template to determine RHAMM mRNA expression levels in these cells by qPCR. Results were analyzed using 
the ΔCt method and normalized to the mean of GAPDH and YWHAZ expression. Data are depicted as mean 2-ΔCt values (+ SD) from 3 
independent donors; ns not significant, *P < 0.05, one-way ANOVA with Bonferroni posthoc test.
Oncotarget73964www.impactjournals.com/oncotarget
other hand, concerns may rise about eliciting auto-
immunity when targeting RHAMM, but so far none of the 
clinical vaccination studies with RHAMM peptide nor our 
own mo-DC trials noted significant toxicity [2, 20, 21].
To conclude, we established that mo-DCs currently 
used as autologous vaccines in cancer patients also express 
RHAMM and sufficiently present it to T cells in an HLA-
dependent manner to allow full activation. Moreover, we 
identified RHAMM-specific T cells within the lymphocyte 
population infiltrating the vaccine sites of AML patients. 
This implies that clinical protocols with mo-DCs also 
vaccinate patients against RHAMM and not only against 
the TAA used to load the DCs.
MATERIALS AND METHODS
Experimental conditions and cell material
This study and reporting thereof is MIATA compliant 
(supplementary MIATA information) [30]. Experiments 
Figure 3: Stimulation of RHAMM R3-specific T cells by DCs. The RHAMM R3-specific cytotoxic CD8+ T cell clone was 
stimulated for 24 hours without DCs (medium control) or with mock EP DCs or RHAMM EP DCs from HLA-A*0201- (n = 5) or A*0201+ 
(n = 3) donors. T cells stimulated with T2 cells ± R3 or R5 peptide served as negative and positive controls. IFN-γ was quantified in 
culture supernatants using ELISA. Data are depicted as mean (+ SD); ns not significant, *P < 0.05, **P < 0.01, one-way ANOVA with 
Bonferroni posthoc test. CD137, CD107a and granzyme B expression by CD8+ T cells was determined by flow cytometry following 24-
hour stimulation with mock EP DCs or RHAMM EP DCs from HLA-A*0201+ donors (n = 2). T cells stimulated with T2 cells + R3 or R5 
peptide served as positive and negative controls, respectively. Data are depicted as mean fluorescence intensity (+SD); ns not significant, 
unpaired t test.
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Figure 4: RHAMM protein expression in AML patient DCs. Two hours after thawing, non EP DCs and WT1 EP DCs were stained 
with LIVE/DEAD® Fixable Red Stain prior to two-step intracellular staining with RHAMM or isotype control mouse IgG1 antibody and 
rat anti-mouse IgG1-PE. Samples were acquired on a FACScan flow cytometer. Data are presented as mean (+ SD) of viable (LIVE/DEAD-) 
DCs from 4 independent donors; ns not significant, **P < 0.01, ***P < 0.001, one-way ANOVA with Bonferroni posthoc test. MFI, mean 
fluorescence intensity.
Figure 5: Stimulation of RHAMM R3-specific T cells by AML patient DCs. The RHAMM R3-specific cytotoxic CD8+ T 
cell clone was stimulated for 24 hours without DCs (medium control) or with WT1 EP DCs from HLA-A*0201- (n = 2) or A*0201+ (n 
= 3) donors. T cells stimulated with T2 cells ± R3 or R5 peptide served as intra-assay controls to validate antigen specificity. IFN-γ was 
quantified in culture supernatants using ELISA. Data are depicted as mean (+ SD); ns not significant, **P < 0.01, ***P < 0.001, one-way 
ANOVA with Bonferroni posthoc test.
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were approved by the Ethics Committee of the University 
of Antwerp, Antwerp, Belgium. Written informed 
consent was obtained for using leftover patient material 
from one of our clinical vaccine trials (clinicaltrials.
gov - NCT00965224). Buffy coats were derived from 
anonymous healthy volunteers’ peripheral blood (with 
citrate phosphate dextrose anticoagulant) donated the 
day before and stored overnight at room temperature 
(Red Cross Blood Transfusion Center Antwerp, Edegem, 
Belgium). Peripheral blood mononuclear cells (PBMCs) 
were isolated from buffy coats by Ficoll density gradient 
separation (Ficoll-Paque PLUS, cat# 17-1440-03, GE 
Healthcare). T2 cells (cat# CRL-1992, American Type 
Culture Collection, Rockville, MD, USA), deficient for 
the transporter associated with antigen processing, were 
cultured in complete medium consisting of Iscove’s 
Modified Dulbecco’s medium (IMDM, cat# 21980-032, 
Thermo Fisher Scientific) with 10% fetal bovine serum 
(FBS; micro-organism pretested and qualified, cat# 10270-
106, Thermo Fisher Scientific). The cytotoxic CD8+ T cell 
clone specific for the HLA-A*0201-restricted R3 epitope 
of RHAMM (amino acids 165-173: ILSLELMKL) was 
kindly provided by Dr. H. Bernhard (Technical University 
of Munich, Munich, Germany) [31]. In all experiments, 
Figure 6: RHAMM-specific CD8+ T cells in vaccinated HLA-A*0201+ AML patients. The graphs on the left show the 
percentage of RHAMM R3 and R5-specific cells within the CD8+ T cell population infiltrating the injection sites of WT1 EP DCs (i.e., the 
vaccine; n = 6) or KLH alone (n = 3). Samples were measured by flow cytometry following staining with R3 or R5 pHLA-A*0201 tetramers. 
Data are depicted as mean (+ SD); *P < 0.05, two-tailed Mann Whitney U test. On the right, dot plots show R3 or R5 pHLA-A*0201 
tetramer staining results of CD8+ T cells isolated from WT1 EP DC or KLH injection site skin biopsies.
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cells were counted using an automated ABX Micros 
60 cell counter (Horiba ABX) and (co-)cultures were 
maintained at 37°C. Cryopreserved cell samples were 
frozen down in FBS with 10% dimethyl sulfoxide (cat# 
D2650, Sigma-Aldrich) in a Nalgene Mr. Frosty™ Cryo 
1 °C freezing container (cat# 5100-0001, ThermoFisher 
Scientific) at −80°C. All experiments were conducted 
in a biosafety level 1-certified laboratory that operates 
under exploratory research principles using established 
laboratory protocols and investigative research assays.
RHAMM messenger RNA
The human RHAMM complementary (c)DNA 
sequence was modified for optimal codon usage and G/C 
content, flanked by the signal sequence and HLA class II-
targeting sequence of DC-lysosome-associated membrane 
protein, [32] and subcloned into a pST1 plasmid vector, 
[33] putting it under the control of a T7 promoter and 
providing it with a poly(A)tail. Messenger (m)RNA 
transcripts were generated using a mMessage mMachine 
T7 in vitro transcription kit (cat# AM1344, Thermo Fisher 
Scientific) according to the manufacturer’s protocol.
DC generation
DCs from anonymous healthy volunteer donors were 
generated according to our AML clinical trial protocol 
(clinicaltrials.gov - NCT00834002, NCT00965224 and 
NCT01686334) with adaptations for research [34]. Briefly, 
CD14+ monocytes were positively selected from fresh 
PBMCs using CD14 MicroBeads (cat# 272-01, Miltenyi 
Biotec) according to the manufacturer’s instructions 
and added to vented T175 culture flasks (cat# 353112, 
Corning) at a final concentration of 1.0-1.4 x 106 cells/
mL in 50-70 mL Roswell Park Memorial Institute (RPMI) 
1640 medium (cat# 21875-034, Thermo Fisher Scientific) 
with 2.5% heat-inactivated human AB serum (micro-
organism pretested and qualified, cat# 34005100, Thermo 
Fisher Scientific), 800 U/mL granulocyte-macrophage 
colony-stimulating factor (cat# CTK-221, Gentaur) and 20 
ng/mL interleukin (IL)-4 (cat# PHC0041, Thermo Fisher 
Scientific). After 5 days, 20 ng/mL tumor necrosis factor-α 
(cat# CTK-223, Gentaur) and 2.5 μg/mL prostaglandin 
E2 (Prostin E2, Pfizer) were added to induce maturation. 
DCs were harvested 40-44 hours later and used as such 
(non EP DCs) or following electroporation without 
mRNA (mock EP DCs) or with 10 μg RHAMM mRNA 
(RHAMM EP DCs) in 200 μL Opti-MEM I reduced serum 
medium without phenol red (cat# 11058-021, Thermo 
Fisher Scientific). Immediately following electroporation, 
DCs were collected and washed in RPMI 1640 medium 
supplemented with 2.5% human AB serum and used in 
further experiments.
DCs from AML patients were thawed from 
cryopreserved aliquots and rested for two hours, before 
further use in experiments in adherence to our clinical 
trial protocol. Using good manufacturing practice-
certified products, these DCs had been generated 
similarly as described above for non EP DCs (controls 
for trial immunomonitoring) or with the addition of KLH 
during maturation and electroporation with WT1 mRNA 
following harvest (WT1 EP DCs; i.e., the clinical vaccine 
product) [2].
RHAMM protein antibody staining
Four hours after electroporation (healthy volunteer 
donor samples) or two hours after thawing (patient 
samples), DCs were stained with LIVE/DEAD® Fixable 
Red Dead Cell Stain (cat# L23102, Thermo Fisher 
Scientific) prior to fixation and permeabilization for 
intracellular staining using the BD Cytofix/Cytoperm™ 
Fixation/Permeabilization Kit (cat# 554714, BD 
Biosciences) according to the manufacturer’s instructions. 
Subsequently, samples were incubated with mouse anti-
RHAMM monoclonal antibody (mAb; clone 2D6, cat# 
MO20030, Neuromics) or isotype control mouse IgG1 
mAb (cat# 349040, BD Biosciences) followed by PE-
labeled rat anti-mouse IgG1 mAb (clone X56, cat# 
340270, BD Biosciences). RHAMM expression in viable 
(LIVE/DEAD-) cells was determined on a FACScan flow 
cytometer (BD Biosciences).
RHAMM mRNA qPCR
Total RNA was prepared from 5 x 105 monocytes 
or mo-DCs immediately after magnetic bead selection 
or electroporation, respectively, using the RNeasy 
Micro Kit (Qiagen). RNA concentration and purity were 
measured on a NanoDrop ND-1000 spectrophotometer. 
Approximately 500 ng of each RNA sample was used 
for synthesizing the cDNA with the iScript™ Advanced 
cDNA Synthesis Kit for RT-qPCR (Bio-Rad) which later 
served as template for a SYBR Green I-based qPCR 
on a LightCycler 480 II (Roche) using the LightCycler 
480 SYBR Green I Master kit (Roche) and the 
following primers (Operon and Biolegio): RHAMM fw 
5’-CAGGTCACCCAAAGGAGTCTCG-3’; RHAMM rv 
5’-CCACTTGATCTGAAGCACAACTAA-3’; GAPDH 
fw 5’-TGCACCACCAACTGCTTAGC-3’; GAPDH rv 
5’-GGCATGGACTGTGGTCATGAG-3’; YWHAZ fw 
5’-ACTTTTGGTACATTGTGGCTTCAA-3’; YWHAZ 
rv 5’-CCGCCAGGACAAACCAGTAT-3’ [18]. All 
procedures were performed according to the respective 
manufacturer’s instructions. RHAMM primers were 
designed to indifferentially amplify the 4 described native 
isoforms of RHAMM [9]. Results were analyzed using the 
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ΔCt method and normalized to the mean of the expression 
of the GAPDH and YWHAZ housekeeping genes.
RHAMM R3-specific cytotoxic CD8+ T cell clone 
activation
The RHAMM R3-specific T cell clone was thawed 
and cultured in triplicate with mock EP DCs, RHAMM 
EP DCs or WT1 EP DCs from HLA-A*0201- or A*0201+ 
donors at a DC:T cell ratio of 4:1 in IMDM supplemented 
with 1% human AB serum in 96-well round bottom 
microplates (cat# 3799, Corning) or sterile capped 5 mL 
tubes (cat# 352054, Corning). Cultures of DCs or T cells 
alone and cultures of T cells with T2 cells ± 5 μg/mL of R3 
or of R5 (RHAMM amino acids 274-282: SLEENIVIL) 
peptide (kind gift by Dr. J. Greiner, University of Ulm, 
Ulm, Germany) served as controls. After 24 hours, 
supernatants were collected and cryopreserved at −20°C 
for IFN-γ quantification or cells were analyzed by 
flow cytometry for CD137, CD107a and granzyme B 
expression.
IFN-γ ELISA
IFN-γ secretion was quantified with a human IFN-γ 
ELISA kit (cat# 900-K27, Peprotech) according to the 
manufacturer’s protocol. Standards and samples were 
measured in duplicate and triplicate, respectively, in a 
96-well flat bottom microplate (cat# 439454, Nunc) on a 
Victor3 multilabel counter (Perkin Elmer).
CD137, CD107a and granzyme B staining
After 24 hours culture, cell samples were stained 
with LIVE/DEAD® Fixable Aqua Dead Cell Stain (cat# 
L34957, Thermo Fisher Scientific), anti-CD3-PerCP-
Cy5.5 (cat# 560835, BD Biosciences), anti-CD8-Pacific 
Blue (cat# MHCD0828, Thermo Fisher Scientific), anti-
CD137-PE (cat# 555956, BD Biosciences) and anti-
CD107a-FITC (cat# 555800, BD Biosciences) for 15 
min at room temperature. Next, CD137 and CD107a 
expression by viable (LIVE/DEAD-) CD3+ CD8+ T cells 
was measured on a FACSAria II flow cytometer (BD 
Biosciences).
Granzyme B production was measured using a 
flow cytometry-based intracellular staining assay. After 1 
hour of DC/T cell co-culture, 1 μL/mL protein transport 
inhibitor (GolgiPlug, cat# 555029, BD Biosciences) was 
added for the remaining 23 hours. After 24 hours, cells 
were stained with LIVE/DEAD® Fixable Aqua Dead 
Cell Stain (cat# L34957, Thermo Fisher Scientific), 
anti-CD3-PerCP-Cy5.5 (cat# 560835, BD Biosciences) 
and anti-CD8-Pacific Blue (cat# MHCD0828, Thermo 
Fisher Scientific) for 15 min at room temperature. Next, 
cells were fixed and permeabilized using the Foxp3/
transcription factor staining buffer kit (cat# 00-5523-00, 
eBioscience) according to the manufacturer’s instructions 
with minor adaptations. Cells were fixed by incubation 
with fix/perm working solution for 1 hour at 4°C, followed 
by two washing steps with permeabilization buffer. 
Permeabilized cells were stained with anti-granzyme 
B-FITC (cat# 560211, BD Biosciences) for 1 hour at 4°C. 
Samples were measured on a FACSAria II flow cytometer 
(BD Biosciences).
RHAMM tetramer staining
Eight weeks after starting biweekly intradermal 
vaccination (i.e., after 4 vaccines) into the upper arms 
near the axilla, a DTH skin test was performed on the 
upper back with single intradermal injections of the 
vaccine or its components, including KLH alone. Two 
days later skin reactions were measured and skin biopsies 
were taken. DTH skin test-infiltrating lymphocytes 
(DILs) were collected and allowed to expand for 2-3 
weeks in medium with 100 IU/mL of IL-2. After harvest, 
RHAMM-specific CD8+ T cells were quantified in DILs 
through flow cytometry following staining with R3 or 
R5 peptide-loaded (p)HLA-A*0201 tetramers (Fred 
Hutchinson Cancer Research Centre Seattle). For each 
condition, 1 x 106 viable thawed DILs were washed and 
stained for 30 min at 4°C with allophycocyanin-labeled 
pHLA-A*0201 tetramers. Samples were then stained 
with LIVE/DEAD® Fixable Aqua Dead Cell Stain (cat# 
L34957, Thermo Fisher Scientific), anti-CD3-PerCP-
Cy5.5 (cat# 560835, BD Biosciences), anti-CD14-FITC 
(cat# 345784 BD Biosciences), anti-CD19-FITC (cat# 
345776, BD Biosciences) and anti-CD8-Pacific Blue 
(cat# MHCD0828, Thermo Fisher Scientific) for another 
30 min at 4°C, followed by detection on a Cyflow ML 
flow cytometer (Partec). Dead (LIVE/DEAD+) cells 
and monocytes and B cells (FITC+) were excluded from 
analysis.
Data analysis
Raw data were routinely checked for consistency 
and plausibility and can be provided upon motivated 
request. All samples were compared empirically to their 
respective negative and positive controls to determine 
reactivity and whether they fell within the ranges of the 
assay. Flow cytometry data were analyzed using FlowJo 
vX.0.6 (Treestar). GraphPad Prism 5 software was used 
for data comparison, statistical calculations and artwork. 
Statistical analysis was performed using one-way analysis 
of variance (ANOVA) with Bonferroni posthoc test or two-
tailed unpaired t test or Mann Whitney U test. Differences 
were predefined to be considered as statistically significant 
when P < 0.05.
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